Sanofi's rivals in the insulin field are nipping at its heels – Lantus sales dipped 5 per cent in the first half of 2015, and analysts don't expect Toujeo to make up for its decline.

In Q3, sales of Lantus were down 9.8% compared with the same period last year, at just under $1.4 billion. Sanofi announced this week plans to cut 20% of jobs in its US diabetes and cardiovascular ...

CHICAGO -- A once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. While Novo lost share to Eli Lilly's once-weekly Trulicity, Ozempic and Rybelsus ...

The table is intended for use as a guide when medications labeled for refrigerated storage are inadvertently exposed to room-temperature. This may occur during routine excursions, power outages ...

MONROE COUNTY, Pa. - Sanofi, maker of anti-inflammation drug Dupixent, will report third-quarter earnings Friday before the opening of U.S. markets. Paris-based Sanofi is the parent company of ...

Both organisations will advance clinical research and development planning, optimise resource allocation and establish the foundational terms for funding and access. DoH and Sanofi are collaborating ...

Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are ...

Sanofi successfully prices €1.5 billion bond issue. Paris, June 17, 2025- Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches:.

Spain’s SpliceBio will use $135 million from a series B round backed by Sanofi and Roche to advance its lead gene editing therapy for Stargardt disease through clinical studies.